Related references
Note: Only part of the references are listed.Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60
Daniel A. Pollyea et al.
BONE MARROW TRANSPLANTATION (2022)
Venetoclax and navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Vinod A. Pullarkat et al.
CANCER DISCOVERY (2021)
Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia
Caitlin R. Rausch et al.
CANCER (2021)
Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs
Lucia Masarova et al.
BLOOD ADVANCES (2021)
Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia
Caitlin R. Rausch et al.
CANCER (2021)
Venetoclax-containing regimens in acute myeloid leukemia
Ibrahim Aldoss et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2021)
Microbiologically documented infections after adult allogeneic hematopoietic cell transplantation: A 5-year analysis within the Swiss Transplant Cohort study
Diem-Lan Vu et al.
TRANSPLANT INFECTIOUS DISEASE (2020)
Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia
Karamjeet S. Sandhu et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Risk of Gvhd and Survival in Patients with Acute Leukemia Who Were Bridged to Allogeneic Stem Cell Transplantation (alloSCT) with Venetoclax-Based Therapy
Akash Mukherjee et al.
BLOOD (2020)
Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies
XiaoYan Yue et al.
CANCER CELL INTERNATIONAL (2020)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome
Andrew H. Wei et al.
BLOOD (2019)
A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome
Amer M. Zeidan et al.
BLOOD (2019)
Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies
Keith W. Pratz et al.
BLOOD (2019)
Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma
Jonathan L. Kaufman et al.
BLOOD (2019)
Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia
Amanda C. Winters et al.
BLOOD ADVANCES (2019)
BCL-2 inhibition in AML: an unexpected bonus?
Marina Konopleva et al.
BLOOD (2018)
Who Is the Patient at Risk of CMV Recurrence: A Review of the Current Scientific Evidence with a Focus on Hematopoietic Cell Transplantation
Jan Styczynski
INFECTIOUS DISEASES AND THERAPY (2018)
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
Courtney D. DiNardo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
Shaji Kumar et al.
BLOOD (2017)
International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium
Andrew C. Harris et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT
Yi Luo et al.
BLOOD (2014)
Bacterial infections in hematopoietic stem cell transplantation recipients
Malgorzata Mikulska et al.
CURRENT OPINION IN HEMATOLOGY (2014)
BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells
Eleni D. Lagadinou et al.
CELL STEM CELL (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction Failure
Michel Duval et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson et al.
BLOOD (2006)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
